Evidence map›Paper›PMID 37867418›Full record

ArticleAmerican journal of hematology2024

Siltuximab administration results in spurious IL-6 elevation in peripheral blood.

Natalie A Mango, Sheila K Pierson, Mateo Sarmiento Bustamante, Joshua D Brandstadter, Frits van Rhee, David C Fajgenbaum

Registry-linked trialOpen access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02817997 (ACCELERATE), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02817997 recruitingnot on this map

ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease

Typeobservational_patient_registrySponsorUniversity of PennsylvaniaRan2016 to 2027Enrolled1,000ConditionsCastleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Natalie A MangoCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0009-0003-1718-0490
Sheila K PiersonCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-3736-1411
Mateo Sarmiento BustamanteCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0009-0002-6774-2714
Joshua D BrandstadterDivision of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Frits van RheeMyeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID 0000-0001-9959-1282
David C FajgenbaumCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-7367-8184
University of Pennsylvania · USWinthrop Rockefeller Foundation · US

Funding

mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic TargetR01HL141408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Taku Kambayashi · 2018 to 2026
$6.1M
ACCELERATE: An Efficient and Innovative Natural History Study Addressing Unmet Needs in Castleman DiseaseR01FD007632 · FDA · UNIVERSITY OF PENNSYLVANIA · PI Joshua D. Brandstadter, David C Fajgenbaum · 2022 to 2026
$2.2M
FDA HHS R01 FD007632NHLBI NIH HHS R01 HL141408NHLBI NIH HHS R01HL141408
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Castleman DiseaseInterleukin-6Antibodies, MonoclonalHumansAntibodies, MonoclonalInterleukin-6siltuximab

Identifiers

PMID37867418
PMCPMC10998478
OpenAlexW4387865952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.